Table 1. Patient with the highest increase in ROS levels had significant drop in ejection fraction.

DCF staining (measure peroxydes) was measured in 4 patients with different oncologic diagnosis prior to treatment (DCF1) and after treatment with DOX (DCF2). Staining was quantified by flow cytometry measurement of mean fluorescence intensity. Echocardiograms were performed at baseline and Ejection Fraction (EF) was recorded then (Pretx EF) and after treatment with DOX (Posttx EF). Patient 2 had near 3-fold increase in DCF staining with a significant drop in EF. Patients 1,3 and 4 did not have significant changes in ROS levels or in EF.

Patient	Diagnosis	Gender	Age (yrs)	Pretx ROS levels	Posttx ROS levels *	Pretx EF	Posttx EF
1	Osteosarcoma	M	16	26.61	42.7	55–60%	55–60%
2	Osteosarcoma	F	16	30.24	89.71	60–65%	44%
3	Osteosarcoma	M	18	23.11	27.41	> 70%	60–65%
4	Unclassified sarcoma	F	4	26.51	49.32	59%	53%